Karyopharm Therapeutics Announces Clinical Trial Collaboration And Supply Agreement With Bristol-Myers Squibb For Mezigdomide Combines With Selinexor Plus Dexamethasone For Relapsed/Refractory Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Karyopharm Therapeutics has announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb. The agreement is for the combination of Mezigdomide with Selinexor and Dexamethasone for the treatment of relapsed/refractory multiple myeloma.
October 30, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol-Myers Squibb has entered into a clinical trial collaboration and supply agreement with Karyopharm Therapeutics, which could potentially enhance its product portfolio.
The collaboration with Karyopharm Therapeutics could potentially enhance Bristol-Myers Squibb's product portfolio and provide a new treatment option for multiple myeloma, which could positively impact its stock in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Karyopharm Therapeutics has announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb, which could potentially enhance its product portfolio and provide a new revenue stream.
The collaboration with Bristol-Myers Squibb could potentially enhance Karyopharm Therapeutics' product portfolio and provide a new revenue stream, which could positively impact its stock in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50